Nkarta Toekomstige groei

Future criteriumcontroles 0/6

De winst van Nkarta zal naar verwachting dalen met 11.5% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 89.6% per jaar. De winst per aandeel zal naar verwachting afnemen met 0.7% per jaar.

Belangrijke informatie

-11.5%

Groei van de winst

-0.7%

Groei van de winst per aandeel

Biotechs winstgroei	28.4%
Inkomstengroei	89.6%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	08 Nov 2024

Recente toekomstige groei-updates

Recent updates

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Nov 20

Nkarta GAAP EPS of -$0.61

Aug 11

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Jun 09

Nkarta: A Promising Natural Killer Cell Play

May 20

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Aug 23

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

May 10

Nkarta gets greenlight from the FDA for NKX019 cancer study

Apr 28

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Jan 25

Winst- en omzetgroeiprognoses

NasdaqGS:NKTX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	2	-161	-176	-136	4
12/31/2025	N/A	-137	-133	-118	6
12/31/2024	N/A	-114	-33	-102	6
9/30/2024	N/A	-111	-108	-98	N/A
6/30/2024	N/A	-108	-110	-94	N/A
3/31/2024	N/A	-116	-117	-94	N/A
12/31/2023	N/A	-118	-114	-86	N/A
9/30/2023	N/A	-122	-127	-70	N/A
6/30/2023	N/A	-125	-123	-65	N/A
3/31/2023	N/A	-119	-110	-59	N/A
12/31/2022	N/A	-114	-104	-57	N/A
9/30/2022	N/A	-104	-80	-67	N/A
6/30/2022	N/A	-98	-78	-71	N/A
3/31/2022	N/A	-93	-77	-72	N/A
12/31/2021	N/A	-86	-73	-68	N/A
9/30/2021	N/A	-81	-68	-63	N/A
6/30/2021	N/A	-72	-62	-57	N/A
3/31/2021	N/A	-102	-56	-50	N/A
12/31/2020	N/A	-91	-51	-44	N/A
9/30/2020	N/A	-84	-44	-37	N/A
6/30/2020	0	-73	-36	-30	N/A
3/31/2020	0	-27	-27	-23	N/A
12/31/2019	0	-21	-20	-18	N/A
12/31/2018	7	0	-6	-5	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat NKTX de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat NKTX de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat NKTX de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat NKTX volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat NKTX volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van NKTX naar verwachting over 3 jaar hoog zal zijn

Nkarta Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 8.7% to US$15.83

Price target decreased by 10% to US$17.33

Price target increased by 7.7% to US$16.00

Price target decreased by 11% to US$17.38

Price target decreased to US$30.36

Price target decreased to US$43.56

Recent updates

Price target decreased by 8.7% to US$15.83

Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade)

Price target decreased by 10% to US$17.33

We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Nkarta, Inc. Announces Executive Appointments

Nkarta, Inc. Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Nkarta, Inc. Appoints George Vratsanos as Board of Directors

Nkarta: A Look Into Q1 Results And Upcoming Catalysts

Nkarta, Inc., Annual General Meeting, Jun 13, 2024

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Nkarta, Inc. has completed a Follow-on Equity Offering in the amount of $240.10001 million.

New minor risk - Shareholder dilution

Nkarta: NK Cell Therapy Advancement On Two Fronts

Nkarta, Inc. has filed a Follow-on Equity Offering in the amount of $240.10001 million.

CEO, President & Director notifies of intention to sell stock

Nkarta: Possible Upside From H1 Update, If Positive

CEO, President & Director recently sold US$85k worth of stock

Price target increased by 7.7% to US$16.00

Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Nkarta, Inc. Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Price target decreased by 11% to US$17.38

We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate

New minor risk - Market cap size

Nkarta, Inc. Appoints Alyssa Levin as Chief Financial Officer

Nkarta, Inc. Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

New minor risk - Share price stability

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Nkarta, Inc. to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Insufficient new directors

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Nkarta, Inc. Promotes David R. Shook to Chief Medical Officer

Price target decreased to US$30.36

Nkarta, Inc. Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

High number of new directors

Nkarta, Inc. to Report Q3, 2022 Results on Nov 09, 2022

CEO, President & Director notifies of intention to sell stock

Nkarta GAAP EPS of -$0.61

Chief Financial & Business Officer exercised options and sold US$71k worth of stock

Nkarta, Inc. Announces Executive Changes

Price target decreased to US$43.56

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Nkarta: A Promising Natural Killer Cell Play

Price target decreased to US$44.11

Nkarta, Inc. Announces Executive Changes

High number of new directors

Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs

Nkarta, Inc., Annual General Meeting, Jun 08, 2022

Nkarta, Inc. Appoints Angela M. Thedinga to its Board of Directors

Price target decreased to US$64.71

Nkarta, Inc. Presents NKX019 Trial in Progress Poster At the 2021 ASH Annual Meeting and Exposition

Insider notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Insider exercised options and sold US$118k worth of stock

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Chief Scientific Officer exercised options and sold US$62k worth of stock

Nkarta, Inc.(NasdaqGS:NKTX) dropped from Russell 2500 Growth Index

CEO, President & Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Chief Financial & Business Officer notifies of intention to sell stock

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer exercised options and sold US$62k worth of stock

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

Nkarta gets greenlight from the FDA for NKX019 cancer study

CEO, President & Director notifies of intention to sell stock

Chief Financial & Business Officer exercised options and sold US$246k worth of stock